Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Wahed FTSE USA Shariah ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Wahed FTSE USA Shariah ETF trades at $76.06 (market cap $996.16M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.9× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Wahed FTSE USA Shariah ETF for 67 Days on average.
| DYN | HLAL | |
|---|---|---|
Market Cap | $2.86B | $996.16M |
Volume | 3,341,579 | 36,084 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $76.54 |
52-Week Low | $14.60 | $57.46 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
